Metabolic research

SURPASS-2: reading a head-to-head diabetes trial

A head-to-head comparison needs its trial population, comparator and endpoint kept in view.

Clinical trialPaper year: 2021Tirzepatide / Semaglutide

01 / DESIGN

What was studied?

This open-label randomized trial compared tirzepatide with a specified semaglutide regimen in 1,879 people with type 2 diabetes over 40 weeks.

02 / FINDINGS

What did the researchers report?

Tirzepatide groups showed greater average reductions in glycated hemoglobin, the primary endpoint, and in body weight. Gastrointestinal adverse events occurred with both treatments.

03 / INTERPRETATION

What are the limits?

The study was open-label and did not compare every possible regimen. It is not a universal ranking of these molecules for every indication, and does not establish interchangeability of research materials with medicines.

Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.

RESEARCH CONTEXT

These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.

What was studied?

What did the researchers report?

What are the limits?

Continue reading.